SpeeDx and Nepean Hospital Awarded Federal Funding for Viral Respiratory Biomarker Test
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, in partnership with researchers from Nepean Blue Mountains Local Health District’s (NBMLHD) Nepean Hospital Intensive Care Unit were awarded funding through the MTPConnect Biomedical Translation Bridge (BTB) program. Funds will support the commercialisation of a respiratory virus host response test – a rapid-response assay to enhance current COVID-19 management activities and future viral pandemic preparedness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200902005970/en/
Utilising newly patented InSignia(TM) technology that enhances the measurement of gene expression, the test will be a rapid, high-throughput tool to support risk-based stratification of patients presenting with respiratory viral illness, including COVID-19. (photo: Sara Eshleman/Wikimedia Commons)
SpeeDx are adapting the NBMLHD laboratory developed test that targets a key genetic marker that is uniquely expressed in response to respiratory virus infection, with levels of the marker correlated with disease progression.1,2 Utilising newly patented In SigniaTM technology that enhances the measurement of gene expression, the commercial test will be a rapid, high-throughput tool to support risk-based stratification of patients presenting with respiratory viral illness, including COVID-19.
“The MTPConnect BTB funding will be instrumental in advancing our commercialisation process and supporting the tight timelines we are setting in order to bring this important product to market” said Colin Denver, SpeeDx CEO.
Delivered by MTPConnect, the Australian Government's BTB program is a $22.3 million MRFF initiative that provides up to $1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
About Nepean and Blue Mountains Local Health District
Nepean Blue Mountains Local Health District is well placed to draw on over 100 years of continuously caring for the community, conducting research and delivering innovation. The Nepean Hospital Intensive Care Unit is part of NBMLHD’s 5,700-strong staff. Being on the frontline of health means NBMLHD has a focus on practical solutions that deliver maximum impact to the health and wellbeing of patients and their families.
References
- Tang BM et al. Eur Respir J. 2017 Jun 15;49(6):1602098.
- https://www.smh.com.au/national/covid-19-blood-test-to-predict-which-patients-will-need-the-most-care-20200406-p54hja.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005970/en/
Contact information
SpeeDx
Australia, New Zealand and Europe
Madeline O’Donoghue - SpeeDx
+61 406 582 808
United States
Rick Roose - RCI Healthcare Public Relations
+1 415 202 4445
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aptiv Powers Intelligent Edge Applications From Automotive to Robotics at CES 20265.1.2026 08:01:00 EET | Press release
Aptiv PLC (NYSE: APTV),a global industrial technology company, will showcase at CES 2026 how its intelligent edge solutions enable devices to sense, think, and act in real time—while continuously optimizing performance throughout their lifecycle. This approach brings advanced computing and artificial intelligence closer to where data is generated, unlocking AI-driven solutions for transportation, robotics, aerospace, and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260104888341/en/ Aptiv Powers the Intelligent Edge from Automotive to Robotics at CES 2026 By processing data locally at the edge, rather than relying solely on centralized cloud systems, Aptiv’s solutions enable faster response time and greater optimization at a system level. “At CES 2026, we’re demonstrating how Aptiv enables real-time perception, decision-making, and actuation—transforming how vehicles and other intelligent, connected devices deliver
Belkin Unveils Next-Generation Chargers, Gaming Power Accessories and More at CES 20264.1.2026 19:00:00 EET | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announced a bold new lineup of accessories designed to power, protect, and enhance the way people work, play, and connect. The new collection, debuting at CES 2026, includes advanced power banks, Qi2 25W wireless chargers, a wireless HDMI dongle for seamless content sharing, and a next gen charging case for the Nintendo Switch 2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260104976028/en/ Belkin unveils new products at CES 2026 Gaming Charging Case Pro for Nintendo Switch 2 (Model ENA003) Engineered for the ultimate on-the-go gaming experience, the Pro case delivers power, protection, and portability in one premium package. A removable 10,000 mAh power bank delivers up to 30W fast charging and features an LCD screen to display remaining battery life. The Pro version builds on the standard model’s safe in‑case charging with a sleeker, integrated power b
Belkin Elevates Everyday Device Protection with a New Lineup of Screen Protectors and a Wear & Tear Program4.1.2026 19:00:00 EET | Press release
Belkin, a leading consumer electronics brand for over 40 years, today announces a new class of screen protection solutions, a strategic partnership, and an all-new wear-and-tear program; advancing its commitment to keeping devices protected and consumers confident. The launch includes seven new screen protectors, a customization partnership with ScreenSkinz, and a screen protection replacement program designed to give users lasting peace of mind and ensure the products they love stay safe, secure, and in the best shape. Meet the ScreenForce Titan Lineup: The Ultimate in Full-Screen Protection Titan SmartShield Titan SmartShield serves as the premium rigid protector in the lineup, delivering aerospace-grade impact resistance and up to 18x the strength of traditional glass*. Engineered with a 9H surface hardness and rated for up to 6.5 ft / 2 m of drop protection**, Titan SmartShield offers exceptional durability without compromising clarity. An advanced anti-reflective coating preserves
SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement4.1.2026 17:13:00 EET | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order governing the Company’s board composition and corporate actions pending trial, and announced the engagement of Zhonghua Certified Public Accountants LLP (“Zhonghua”), an affiliate of the global accounting network UHY International, as the Company’s independent auditor and registered public accounting firm. Update on Antigua High Court Order Further to the order issued by the Antigua High Court (the “Court”) previously disclosed by the Company in a press release dated December 17, 2025, the Court has updated its order to provide that directors Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Dr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Weidong Yin (collectively, the “Board”), will comprise the Board of the Company until the trial liste
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report4.1.2026 17:00:00 EET | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq’s Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025. As previously disclosed, the Company received a delisting determination letter (the “Staff Determination”) from Nasdaq in November 2025. The Company requested a hearing before the Nasdaq Hearings Panel to appeal the Staff Determination on November 19, 2025. Nasdaq has informed the Company that the Nasdaq Hearings Panel will also consider the matter addressed in the Notification Letter at a hearing scheduled for January 8, 2026 at which the Company has been invited to present
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom